Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $26.8 million.

  • Ironwood Pharmaceuticals' Accumulated Expenses rose 3.14% to $34.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.6 million, marking a year-over-year increase of 3.14%. This contributed to the annual value of $26.8 million for FY2024, which is 39.33% down from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Accumulated Expenses is $26.8 million, which was down 39.33% from $44.3 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Accumulated Expenses ranged from a high of $44.3 million in FY2023 and a low of $16.7 million during FY2022.
  • Its 3-year average for Accumulated Expenses is $29.3 million, with a median of $26.8 million in 2024.
  • In the last 5 years, Ironwood Pharmaceuticals' Accumulated Expenses surged by 164.99% in 2023 and then crashed by 39.33% in 2024.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Accumulated Expenses stood at $26.5 million in 2020, then decreased by 11.02% to $23.6 million in 2021, then decreased by 29.14% to $16.7 million in 2022, then surged by 164.99% to $44.3 million in 2023, then tumbled by 39.33% to $26.8 million in 2024.